Advertisement

Tocainide

  • Adam Schneeweiss
  • Gotthard Schettler
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 72)

Abstract

Tocainide is a new antiarrhythmic agent that has recently been approved for oral use in the United States. The approved indication is treatment of symptomatic ventricular arrhythmias. It was developed from lidocaine in an attempt to overcome the disadvantages of this agent, namely, the low oral bioavailability, short half-life, and narrow therapeutic-toxic ratio.

Keywords

Acute Myocardial Infarction Ventricular Tachycardia Ventricular Arrhythmia Ventricular Fibrillation Antiarrhythmic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Winkle RA, et al: Tocainide for drug resistant ventricular arrhythmias: efficacy, side effects, and lidocaine responsiveness for predicting tocainide success. Am Heart J 100:1031, 1980.PubMedCrossRefGoogle Scholar
  2. 2.
    Almotrefi AA, Baker JBE: The antifibrillatory potency of aprindine, mexiletine, tocainide and lignocaine compared on Langendorff perfused hearts of rabbits and guinea-pigs. J Pharm Pharmacol 32:746, 1980.PubMedCrossRefGoogle Scholar
  3. 3.
    Moore, et al: Electrophysiologic properties of a new antiarrhythmic drug: tocainide. Am J Cardiol 41:703, 1978.PubMedCrossRefGoogle Scholar
  4. 4.
    Anderson JL, et al: Clinical electrophysiologic effects of tocainide. Circulation 57:685, 1978.PubMedGoogle Scholar
  5. 5.
    Horowitz LN, et al: Human electropharmacology of tocainide, a lignocaine congener. Am J Cardiol 42:276, 1978.PubMedCrossRefGoogle Scholar
  6. 6.
    Morganroth J, et al: A review of the uses and limitations of tocainide: a class 1B antiarrhythmic agent. Am Heart J 110:856, 1985.PubMedCrossRefGoogle Scholar
  7. 7.
    Ryden L, et al: Prophylaxis of ventricular tachyarrhythmias with intravenous and oral tocainide in patients with and recovering from acute myocardial infarction. Am Heart J 100:1006, 1980.PubMedCrossRefGoogle Scholar
  8. 8.
    Haffajee CI, et al: Chronic tocainide therapy for refractory high-grade ventricular arrhythmias. Clin Cardiol 6:72, 1983.PubMedCrossRefGoogle Scholar
  9. 9.
    Campbell RWF, et al: Oral tocainide in suspected acute myocardial infarction. Circulation 60:70, 1970.Google Scholar
  10. 10.
    Roden DM, et al: Tocainide therapy for refractory ventricular arrhythmias. Am Heart J 100:15, 1980.PubMedCrossRefGoogle Scholar
  11. 11.
    Winkle RA, et al: Tocainide for drug resistant ventricular arrhythmias: efficacy, side effects, and lignocaine responsiveness for predicting tocainide success. Am Heart J 100:1031, 1980.PubMedCrossRefGoogle Scholar
  12. 12.
    Maloney JD, et al: Open clinical studies at a referral centre: chronic maintenance tocainide therapy in patients with recurrent sustained ventricular tachycardia refractory to conventional antiarrhythmic agents. Am Heart J 100:1023, 1980.PubMedCrossRefGoogle Scholar
  13. 13.
    Waleffe A, et al: Effects of tocainide studied with programmed electrical stimulation of the heart in patients with reentrant tachyarrhythmias. Am J Cardiol 43:292, 1979.PubMedCrossRefGoogle Scholar
  14. 14.
    Keefe DL, et al: Prophylactic tocainide or lidocaine in acute myocardial infarction. Am J Cardiol 57:527, 1986.PubMedCrossRefGoogle Scholar
  15. 15.
    Nyquist O, et al: Hemodynamic and antiarrhythmic effects of tocainide in patients with acute myocardial infarction. Am Heart J 100:1000, 1980.PubMedCrossRefGoogle Scholar
  16. 16.
    Ryan WF, Karliner JS: Effects of tocainide on left ventricular performance at rest and during acute alterations in heart rate and systemic arterial pressure. Br Heart J 41:175, 1979.PubMedCrossRefGoogle Scholar
  17. 17.
    Ikram H: Hemodynamic and electrophysiologic interactions between antiarrhythmic drugs and beta-blockers with special reference to tocainide. Am Heart J 100:1076, 1980.PubMedCrossRefGoogle Scholar
  18. 18.
    Lalka D, et al: Kinetics of the oral antiarrhythmic lidocaine congener, tocainide. Clin Pharmacol Ther 19:757, 1976.PubMedGoogle Scholar
  19. 19.
    Craffner C, et al: Tocainide kinetics after intravenous and oral administration in healthy subjects and in patients with acute myocardial infarction. Clin Pharmacol Ther 27:64, 1980.CrossRefGoogle Scholar
  20. 20.
    Elvin AT, et al: Tocainide kinetics and metabolism: effects of phenobarbitone and substrates for glucuronyl transferase. Clin Pharmacol Ther 27:652, 1980.CrossRefGoogle Scholar
  21. 21.
    Ronfeld PA et al: Tocainide and metabolites: human pharmacokinetics and animal pharmacology. Clin Pharmacol Ther 27:282, 1980.Google Scholar
  22. 22.
    Woosley RL, et al: Suppression of ventricular ectopic depolarizations by tocainide. Circulation 56:980, 1977.PubMedGoogle Scholar
  23. 23.
    Winkle RA, et al: Clinical efficacy and pharmacokinetics of a new orally effective antiarrhythmic, tocainide. Circulation 54:884, 1976.Google Scholar
  24. 24.
    Weigers U: Pharmacokinetics of tocainide in patients with endstage renal failure. In: Pottage, Ryden L (eds) Workshop on tocainide: proceedings from a conference held in Copenhagen, 1979. AB Hassle, Moindal, Sweden, 1981, p 100.Google Scholar
  25. 25.
    Holmes B, et al: Tocainide: a review of its pharmacological properties and therapeutic efficacy. Drugs 26:93, 1983.PubMedCrossRefGoogle Scholar
  26. 26.
    Mandai SK, Datta SK: Nodal bradycardia induced by tocainide. Postgrad Med J 59:262, 1983.CrossRefGoogle Scholar
  27. 27.
    Engle TL, Le Winter M: Tocainide-induced ventricular fibrillation. Am Heart J 101:494, 1981.CrossRefGoogle Scholar
  28. 28.
    Velebit V, et al: Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 65:886, 1982.PubMedCrossRefGoogle Scholar
  29. 29.
    Holt DW, et al: Dosage schedules for the transition from intravenous lignocaine to oral tocainide following acute myocardial infarction. Br J Clin Pharmacol 14:586P, 1982.Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1988

Authors and Affiliations

  • Adam Schneeweiss
    • 1
  • Gotthard Schettler
    • 2
  1. 1.Geriatric Cardiology Research FoundationTel-AvivIsrael
  2. 2.Department of MedicineUniversity of HeidelbergGermany

Personalised recommendations